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Abstract
Background: The CXCR4 chemokine receptor regulates migration and homing of cancer cells to specific metastatic sites.
Determination of the CXCR4 receptor status will provide predictive information for disease prognosis and possible
therapeutic intervention. However, previous attempts to localize CXCR4 using poorly characterized mouse monoclonal or
rabbit polyclonal antibodies have produced predominant nuclear and occasional cytoplasmic staining but did not result in
the identification of bona fide cell surface receptors.
Methodology/Principal Findings: In the present study, we extensively characterized the novel rabbit monoclonal anti-
CXCR4 antibody (clone UMB-2) using transfected cells and tissues from CXCR4-deficient mice. Specificity of UMB-2 was
demonstrated by cell surface staining of CXCR4-transfected cells; translocation of CXCR4 immunostaining after agonist
exposure; detection of a broad band migrating at Mr 38,000–43,000 in Western blots of homogenates from CXCR4-
expressing cells; selective detection of the receptor in tissues from CXCR4+/+ but not from CXCR42/2 mice; and abolition
of tissue immunostaining by preadsorption of UMB-2 with its immunizing peptide. In formalin-fixed, paraffin-embedded
human tumor tissues, UMB-2 yielded highly effective plasma membrane staining of a subpopulation of tumor cells, which
were often heterogeneously distributed throughout the tumor. A comparative analysis of the mouse monoclonal antibody
12G5 and other frequently used commercially available antibodies revealed that none of these was able to detect CXCR4
under otherwise identical conditions.
Conclusions/Significance: Thus, the rabbit monoclonal antibody UMB-2 may prove of great value in the assessment of the
CXCR4 receptor status in a variety of human tumors during routine histopathological examination.
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Introduction
The CXCR4 chemokine receptor is a plasma membrane
receptor that regulates an array of trafficking events during
organogenesis, hematopoesis and inflammation [1]. The specific
ligand to CXCR4, stromal cell-derived factor 1 (SDF-1,
CXCL12), is expressed at high levels in lymph nodes, lungs, bone
marrow and liver. Recent studies indicate that CXCR4 is one of
the critical factors for metastasis homing on specific organ sites in
that SDF-1 released in target organs may attract nearby or distant
CXCR4-expressing cancer cells [2]. Inhibition of the CXCR4-
SDF-1-axis by specific CXCR4 antagonists or RNA interference
has been shown to block in vitro invasion and in vivo metastasis of
cancer cells in animal models [3,4,5]. In fact, expression of
CXCR4 in a number of human malignancies has been shown to
increase the risk for recurrence and poor survival [6,7,8,9]. Thus,
an accurate assessment of the CXCR4 status of a given tumor
specimen would provide valuable predictive information for
disease prognosis and possible therapeutic intervention.
Consequently, much attention has been directed towards the
detection and localization of CXCR4 receptors in human primary
tumors. Earlier studies have assessed CXCR4 expression using
reverse transcription-polymerase chain reaction (RT-PCR) [2,6].
However, the diagnostic value of this method is limited. RT-PCR
is based on total RNA isolation from a fresh tumor sample and
would therefore not only detect CXCR4 receptor transcripts
originating from tumor cells but also from lymphocytes,
endothelial cells or other non-malignant cells. Other studies have
utilized the mouse monoclonal antibodies {12G5} and {44716}
for immunohistochemical detection of CXCR4 in human
formalin-fixed, paraffin-embedded tumors [7,8,9,10,11,12,13,
14,15,16,17,18,19,20]. These antibodies have been generated by
immunizing mice with live CXCR4-expressing cells and presum-
ably bind to an extracellular domain of the receptor [21,22].
Unfortunately, specific epitope information is not available for
{12G5} and {44716}, which eliminates the possibility to perform
adsorption controls during immunohistochemical staining. Al-
though flow cytometric analysis suggests that {12G5} and
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4069{44716} can bind to CXCR4 on native cells, these antibodies
have not been adequately characterized using fixed cells or tissues
[21,22]. In fact, virtually all-previous studies using these and other
commercially available antibodies have reported predominant
staining of cell nuclei with occasional cytoplasmic staining in
human fixed-embedded tissues [7,8,9,10,11,12,13,14,15,16,17,18,
19,20,23]. Given our understanding of CXCR4 signaling, an
entirely nuclear localization would not be compatible with a
function of this receptor in cancer cell migration and homing [1].
In the present study, we have extensively characterized the new
rabbit monoclonal anti-CXCR4 antibody UMB-2, which is
directed against the carboxyl-terminal tail of the receptor. We
demonstrate that UMB-2 selectively detects its cognate receptor in
fixed cells and tissues. In contrast to currently available
monoclonal and polyclonal antibodies, UMB-2 efficiently detects
bona fide CXCR4 plasma membrane receptors. Thus, the
development of UMB-2 will now allow the establishment of
guidelines for routine performance of CXCR4 immunohisto-
chemistry in human tumors.
Materials and Methods
Antibodies
Rabbit polyclonal anti-CXCR4 antibodies {2144} and {1181}
were generated against the following sequence KGKRGGHS-
SVSTESESSSFHSS, which corresponds to residues 338–359 of
the human CXCR4 receptor. This sequence is identical in mouse,
rat and human CXCR4 receptors. Anti-CXCR4 antibodies
{2144} and {1181} have been extensively characterized previ-
ously in mouse and rat tissues [24,25,26,27,28]. Rabbit monoclo-
nal anti-CXCR4 antibody clone UMB-2 was generated against
the identical sequence and obtained from Epitomics (Burlingame,
CA). Rabbit polyclonal anti-CCR7 {1188} was generated against
the following sequence CRHIRRSSMSVEAETTTTFSP, which
corresponds to residues 358-378 of the human CCR7 receptor.
Anti-CCR7 antibody was then affinity purified against its
immunizing peptide. The mouse monoclonal anti-CXCR4
antibodies {12G5} and {44716} were obtained from R&D
Systems (Minneapolis, MN). The goat polyclonal anti-CXCR4
antibody {6190} was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA).
Tumor Samples
The following tumors were investigated: breast carcinoma
(n=36); ovarian carcinoma (n=22); cervical carcinoma (n=16);
endometrial carcinoma (n=4); gastric cancer (n=13), colorectal
adenocarcinoma (n=23); pancreatic adenocarcinoma (n=29);
prostate cancer (n=24); carcinoid (n=18), growth hormone-
secreting pituitary adenoma (n=8); pheochromocytoma (n=20);
glioblastoma multiforme (n=18); astrocytoma grade II (n=8);
astrocytoma grade III (n=8). All tissue specimens had been fixed
in formalin and were then embedded in paraffin.
Immunocytochemistry
Plasmids encoding the human CXCR4 and human CCR7
receptors were obtained from UMR cDNA Resource Center
(Rolla, MO). Human embryonic kidney 293 (HEK-293) cells were
stably transfected with either CXCR4 or CCR7. Cells were grown
on coverslips overnight and either not exposed or exposed to
100 ng/ml SDF-1 or 100 ng/ml MIP-3 (R&D Systems). Cells
were then fixed and incubated with anti-CCR7 {1188, 1 mg/ml},
anti-CXCR4 {UMB-2, hybridoma supernatant at a dilution of
1:100}, anti-CXCR4 {6190, 1–10 mg/ml}, anti-CXCR4 {44716,
5–15 mg/ml} or anti-CXCR4 {12G5, 1–25 mg/ml} antibodies
followed by the appropriate cyanine 3.18-conjugated secondary
antibodies (Amersham, Braunschweig, Germany). Specimens were
mounted and examined using a Leica TCS-NT laser scanning
confocal microscope as described [29].
Western blot analysis
HEK-293 cells stably transfected with CCR7 or CXCR4 as well
as brains from CXCR4-deficient mice and their wild-type
littermates were lysed in detergent buffer (20 mM Hepes,
pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 10%
glycerol, 0.1% SDS, 0.2 mM phenylmethylsulfonylfluoride,
10 mg/ml leupeptin, 1 mg/ml pepstatin A, 1 mg/ml aprotinin
and 10 mg/ml bacitracin) and glycoproteins were enriched using
wheat germ lectin agarose beads as described [26]. Beads were
washed 5 times in detergent buffer, and proteins were eluted with
SDS-sample buffer for 20 min at 60uC. Samples were then
subjected to 10% SDS-polyacrylamide gel electrophoresis and
immunoblotted onto nitrocellulose. Blots were incubated with
anti-CCR7 {1188, 1 mg/ml}, anti-CXCR4 {UMB-2, 1:100},
anti-CXCR4 {6190, 1–10 mg/ml}, anti-CXCR4 {44716, 5–
15 mg/ml} or anti-CXCR4 {12G5, 1–25 mg/ml} antibodies
followed by the appropriate peroxidase-conjugated secondary
antibodies and enhanced chemiluminescence detection (Amer-
sham, Braunschweig, Germany). For all animal procedures, ethical
approval was sought before the experiments according to national
and institutional requirements.
Immunohistochemistry
Seven mm paraffin sections were cut and floated onto positively
charged slides and immunohistochemically stained as described.
For antigen retrieval, sections were microwaved in 10 mM citric
acid (pH 6.0) for 20 min at 600 W. Specimens were then
incubated with anti-CXCR4 {UMB-2, 1:10}, anti-CXCR4
{6190, 1–10 mg/ml}, anti-CXCR4 {44716, 5–15 mg/ml} or
anti-CXCR4 {12G5, 1–25 mg/ml} antibodies overnight at 4uC.
Staining of primary antibody was detected using the appropriate
biotinylated secondary antibodies followed by incubation with
avidin-biotinylated peroxidase solution. Tissue was then rinsed
and stained with diaminobenzidine for 15 min. Cell nuclei were
lightly counterstained with hematoxylin. For immunohistochem-
ical controls, the primary antibody was either omitted or adsorbed
with homologous or heterologous peptides for 2 h at room
temperature.
Results
Characterization of Rabbit Monoclonal anti-CXCR4
Antibody UMB-2
Specificity of anti-CXCR4 antibody {UMB-2} was monitored
using Western blot analysis of extracts prepared from CXCR4-
expressing and CCR7-expressing HEK 293 cells. When mem-
brane preparations from these cells were electrophoretically
separated and blotted onto nitrocellulose, UMB-2 revealed a
single broad band migrating at Mr 38,000 to 43,000 only in cells
transfected with CXCR4 but not in CCR7-transfected cells
(Figure 1 A, right panel). The rabbit polyclonal anti-CXCR4
antibodies {2144} and {1181} yielded identical results [26].
Conversely, the anti-CCR7 antibody {1188} detected a broad
band migrating at Mr 40,000 to 60,000 only in CCR7-transfected
cells but not in HEK-293 cells stably expressing CXCR4 (Figure 1
A, left panel). In contrast, the mouse monoclonal anti-CXCR4
antibody {12G5} and two other commercially available anti-
CXCR4 antibodies were not able to detect the CXCR4 receptor
in the same samples under identical conditions (Supplemental
Rabbit Monoclonal CXCR4
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2} was further characterized using immunofluorescent staining of
transfected cells. When HEK-293 cells stably expressing CXCR4
or CCR7 were stained with UMB-2, prominent immunofluores-
cence localized at the level of the plasma membrane was selectively
detected in cells expressing CXCR4 (Figure 1 B, right panel). After
incubation with SDF-1, CXCR4 immunostaining was translocat-
ed from the plasma membrane into the cytosol indicating rapid
agonist-induced endocytosis of the receptor (Figure 1 B, right panel).
The rabbit polyclonal anti-CXCR4 antibodies {2144} and
{1181} yielded identical results [26]. Conversely, the anti-CCR7
antibody {1188} detected its cognate receptor at the plasma
membrane of CCR7-transfected cells but not in CXCR4-
expressing cells (Figure 1 B, left panel). CCR7 immunostaining
was translocated from the plasma membrane into the cytosol after
exposure to MIP-3 (Figure 1 B, left panel). In contrast, under
identical conditions none of the commercially available antibodies
was able to discriminate between CXCR4- and CCR7 expressing
cells (Supplemental Figure S1). Immunofluorescence was either
not detectable {6190}, present at the cell nucleus {12G5} or at the
cell surface {44716} but in each case completely unrelated to
CXCR4 (Supplemental Figure S1).
Specificity of UMB-2 was then monitored in Western blot
experiments using tissues from CXCR4-deficient mice and their
wild-type littermates. The sequence used to generate UMB-2 is
identical in mice, rats and humans. Using the rabbit polyclonal
anti-CXCR4 antibodies {2144} and {1181}, we have previously
shown that the CXCR4 receptor is expressed in distinct
populations of neurons in the embryonic brain and that CXCR4
expression strongly declines during development [24,25,27]. In
crude extracts from embryonic brain tissue (E17) of wild-type mice
(CXCR4+/+), UMB-2 detected a broad band migrating at Mr
38,000 to 43,000, which corresponds to the expected size of the
CXCR4 receptor (Figure 2 A, right panel). In contrast, UMB-2 did
not detect any immunoreactive band in embryonic brain extracts
from CXCR4-deficient mice (Figure 2 A, left panel) and only a very
weak band in brain extracts from adult CXCR4+/+ mice (Figure 2
A, right panel). When forebrain sections of embryonic mice (E17)
were immunohistochemically stained, UMB-2 yielded the well-
known CXCR4 staining pattern with prominent immunoreactivity
in the cortex, caudate putamen, ganglionic eminence in
CXCR4+/+ mice but not in CXCR42/2 mice (Figure 2 B–E).
At higher magnification it became apparent that CXCR4
immunostaining decorated the plasma membrane of tangentially
migrating neurons in the cortex (Figure 2 F).
UMB-2 Immunohistochemistry in Normal and Neoplastic
Human Tissues
First, UMB-2 was tested on a variety of formalin-fixed, paraffin-
embedded human breast cancers, which have previously been
reported to express CXCR4 [2]. Initial experiments revealed that
UMB-2 yielded highly effective immunohistochemical staining of
fixed-embedded tissues with a predominance of plasma membrane
staining and very low cytoplasmic signal (Figure 3 A). Initial
experiments also demonstrated that UMB-2 detected CXCR4
receptors in fixed-embedded human tissues even without heat-
Figure 1. Characterization of rabbit monoclonal antibody
UMB-2 using transfected cells. A, Western blot analysis of the
specificity of anti-CXCR4 antibodies. Membrane preparations from HEK-
293 cells stably transfected to express either CCR7 or CXCR4 were
separated on 10% SDS-polyacrylamide gels and blotted onto nitrocel-
lulose membranes. Membranes were then incubated with affinity-
purified 1 mg/ml anti-CCR7 {1188} or anti-CXCR4 {UMB-2} hybridoma
supernatant at a dilution of 1:100. Blots were developed using
enhanced chemiluminescence. Note that UMB-2 detected a band of
the expected molecular weight only in CXCR4- but not in CCR7-
transfected cells. Two additional experiments gave similar results.
Ordinate, migration of protein molecular weight markers (Mr610
23). B,
characterization of UMB-2 by immunofluorescent staining of transfect-
ed cells. HEK-293 cells expressing CCR7 or CXCR4 were either not
exposed or exposed to 100 ng/ml MIP-3 or 100 ng/ml SDF-1 for 30 min,
subsequently fixed and immunofluorescently stained with 1 mg/ml anti-
CCR7 {1188} or anti-CXCR4 {UMB-2} at a dilution of 1:100. Note that
UMB-2 detected prominent immunofluorescence at the level of the
plasma membrane only in CXCR4- but not in CCR7-expressing cells, and
that SDF-1 exposure induced a rapid translocation of CXCR4 receptor
immunostaining from the plasma membrane into the cytosol.
Representative results from one of three independent experiments
are shown. Scale bar, 20 mm.
doi:10.1371/journal.pone.0004069.g001
Rabbit Monoclonal CXCR4
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immunostaining was not uniformly present on all tumor cells but
rather heterogeneously distributed throughout the tumor
(Figure 3). UMB-2 immunostaining was completely abolished by
preadsorption of the antibody with 10 mg/ml of its immunizing
peptide (Figure 3 C).
A series of 247 human tissue samples was then immunohisto-
chemically stained with UMB-2. Prominent CXCR4 staining of
the tumor cells was observed in a number of mammary,
pancreatic, prostate, cervical and ovarian carcinomas (Table 1,
Figure 3). UMB-2 immunostaining was not detected in GH-
secreting pituitary adenomas and pheochromocytomas except for
one case of a malignant pheochromocytoma (Table 1, Figure 3).
As depicted in Figures 3 A, B, C, D, F, G, and J robust plasma
membrane staining of tumor cells was most frequently observed.
In contrast, a number of prostate carcinomas presented with
punctuate cytoplasmic staining (Figure 3 H). However, in virtually
none of our cases CXCR4 receptors were detected at cell nuclei
(Figure 3). CXCR4 was also frequently detected on tumoral micro
vessels (Table 1). In our cases, CXCR4 was not observed on tumor
cells in astrocytomas or glioblastomas. It should be noted,
however, that CXCR4 was found on a high density on vascular
endothelial cells in glioblastoma multiforme but never in
astrocytomas grade I or II. UMB-2 also facilitated detection of
CXCR4 receptors in non-neoplastic tissues, i.e. prominent UMB-
2 immunostaining was seen in the zona fasciculata of the adrenal
cortex but not in the adrenal medulla (Figure 3 K).
Finally, the rabbit monoclonal anti-CXCR4 antibody {UMB-
2} was compared with mouse monoclonal antibody 12G5 and
other frequently used commercially available antibodies. As
depicted in Supplemental Figure S2, UMB-2 immunohistochem-
istry allowed a clear discrimination between CXCR4-positive and
CXCR4-negative tumors. In contrast, under identical conditions
commercially available antibodies yielded either no detectable
immunostaining {6190} or prominent staining of cell nuclei
{44716} and/or occasional cytoplasmic staining {12G5} (Sup-
plemental Figure S2).
Discussion
In an effort to study the pattern of CXCR4 receptor protein
expression in human normal and neoplastic tissues, we extensively
characterized the novel rabbit monoclonal anti-CXCR4 antibody
{UMB-2}. Our results demonstrate that the cytoplasmic tail of the
CXCR4 receptor can serve as an epitope for the generation of
monoclonal antibodies that effectively stain formalin-fixed, paraffin-
embedded human and rodent tissues. Several lines of evidence
indicate that UMB-2 specifically detects its targeted receptor and
does not crossreact. First, in Western blots of membranes from
CXCR4-transfected cells UMB-2 detected a broad band migrating
at Mr 38,000–43,000. Second, UMB-2 revealed prominent cell
Figure 2. Characterization of rabbit monoclonal antibody
UMB-2 using CXCR4-deficient mice. A, Western blot analysis of
the specificity of UMB-2 using brain homogenates from CXCR4-deficient
mice (CXCR42/2) prepared at embryonic day 17 (E17) and their wild-
type littermates (CXCR4+/+) as well adult CXCR4+/+ brain prepared at
postnatal day 90 (P90). Note that UMB-2 selectively detects CXCR4
receptors at E17 in CXCR4+/+ mice and does not cross-react with other
proteins present in tissue extracts prepared from CXCR42/2 mice.
Migration of protein molecular weight markers (Mr610
23) is indicated
on the right. B–E, characterization of UMB-2 by immunohistochemical
staining of formalin-fixed, paraffin-embedded brain sections prepared
at E17 from CXCR4-deficient mice (CXCR42/2, left panel) and their
wild-type littermates (CXCR4+/+, right panel). Note that UMB-2
selectively detects CXCR4 receptors and does not cross-react with
other proteins present in tissue sections from CXCR42/2 mice. F,
prominent CXCR4 receptor immunostaining at the plasma membrane
of tangentially migrating neurons in the cortex. CTX, cortex; GE,
ganglionic eminence; CPu, caudate putamen; OX, optic chiasm; 3V,
third ventricle; MZ, marginal zone; CP, cortical plate; IZ, intermediate
zone; SVZ, subventricular zone; VZ, ventricular zone. Scale bars,
B=C=500 mm, D=E=100 mm, F=50 mm.
doi:10.1371/journal.pone.0004069.g002
Rabbit Monoclonal CXCR4
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translocated from the cell surface into the cytosol after SDF-1
exposure. Third, UMB-2 clearly detected CXCR4 receptors in
homogenates and tissue sections from wild-type mice but not in
tissues from CXCR4-deficient mice. Fourth, UMB-2 detected bona
fide plasma membrane receptors in fixed-embedded human tissues.
Finally, UMB-2 immunostaining was completely abolished by
preadsorption with its immunizing peptide.
In contrast to currently available anti-CXCR4 antibodies, the
novel rabbit monoclonal antibody UMB-2 yielded highly effective
plasma membrane staining of tumor cells without any detectable
immunostaining of cell nuclei. The plasma membrane localization
would be compatible with our understanding of CXCR4 function
in cancer cell migration and homing [1]. However, it should be
noted that in the majority of tumors CXCR4 immunostaining was
heterogeneously distributed throughout the tumor and not
uniformly present on all tumor cells. Interestingly, CXCR4
immunostaining was also frequently observed in tumoral micro
vessels in glioblastoma multiforme but not in astrocytomas. The
use of UMB-2 also permitted us to gain novel insights into
CXCR4 receptor expression in normal tissues, e.g. CXCR4 was
detected for the first time in the Zona fasciculata of the adrenal
cortex. However, the precise function of CXCR4 in the regulation
cortisol production or secretion needs to be established.
The rabbit monoclonal antibody UMB-2 will overcome a
number of limitations of currently available antibodies, e.g. the
Figure 3. UMB-2 immunohistochemical staining in human formalin-fixed and paraffin-embedded tissues. A–K,U M B - 2
immunohistochemical staining of a variety of human normal and neoplastic tissues. Sections were dewaxed, microwaved in citric acid and
incubated with UMB-2 at a dilution of 1:10. Sections were sequentially treated with biotinylated anti-rabbit IgG and AB solution. Sections were then
developed in diaminobenzidine and lightly counterstained with hematoxylin. Note that UMB-2 detected CXCR4 receptors at the plasma membrane of
a subset of tumor cells in a variety of human tumors including mammary carcinoma (A), endometrial carcinoma (B), cervical carcinoma (C), ovarian
carcinoma (D), gastric carcinoma (E), pancreatic carcinoma (F), colonic carcinoma (G) and malignant pheochromocytoma (J). In nearly all of these
cases UMB-2 immunoreactive tumor cells exhibited a heterogeneous distribution throughout the tumor. UMB-2 revealed predominant cytoplasmic
staining in prostate carcinoma (H). In glioblastoma, UMB-2 detected CXCR4 receptors predominantly on the plasma membrane of endothelial cell of
tumoral blood vessels (I). UMB-2 also detected CXCR4 receptors in the zona fasciculata of the adrenal cortex (K). Inset in C, peptide adsorption control.
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bodies have only been selected for their binding to native receptors
on living cells and have not been adequately characterized on
fixed cells and tissues [21,22]. In addition, only limited epitope
information is available which prevents the inclusion of adsorption
controls during immunohistochemical staining [21,22]. Thus, the
development of UMB-2 will now allow the establishment of
guidelines for the routine performance and interpretation of
CXCR4 immunohistochemistry in a variety of human tumors.
Supporting Information
Figure S1 Comparative analysis of UMB-2 and currently
available CXCR4 antibodies using transfected cells. A, Western
blot analysis of the specificity of anti-CXCR4 antibodies.
Membrane preparations from HEK-293 cells stably transfected
to express either CCR7 or CXCR4 were separated on 10% SDS-
polyacrylamide gels and blotted onto nitrocellulose membranes.
Membranes were then incubated with 1 mg/ml anti-CCR7
{1188}, anti-CXCR4 {UMB-2} hybridoma supernatant at a
dilution of 1:100, 10 mg/ml anti-CXCR4 {6190}, 15 mg/ml anti-
CXCR4 {44716} or 25 mg/ml anti-CXCR4 {12G5} antibodies.
Blots were developed using enhanced chemiluminescence. Note
that only UMB-2 detected the appropriate CXCR4 receptor
band. Ordinate, migration of protein molecular weight markers
(Mr61023). B, characterization of CXCR4 antibodies by
immunofluorescent staining of transfected cells. B, HEK-293 cells
stably transfected to express CCR7 or CXCR4 were either not
exposed or exposed to 100 ng/ml MIP-3 or 100 ng/ml SDF-1 for
30 min, and subsequently fixed and immunofluorescently stained
with 1 mg/ml anti-CCR7 {1188}, anti-CXCR4 {UMB-2} at a
dilution of 1:100, 10 mg/ml anti-CXCR4 {6190}, 15 mg/ml anti-
CXCR4 {44716} or 25 mg/ml anti-CXCR4 {12G5} antibodies.
UMB-2 selectively detected plasma membrane immunofluores-
cence in CXCR4-expressing cells that rapidly translocated into the
cytosol after SDF-1 exposure. Note that none of the commercially
available antibodies was able to detect CXCR4 in fixed cells or cell
lysates under otherwise identical conditions. Representative results
from one of two independent experiments are shown. Scale bar,
20 mm.
Found at: doi:10.1371/journal.pone.0004069.s001 (3.80 MB TIF)
Figure S2 Comparative analysis of immunohistochemical stain-
ing of human tissues using UMB-2 and currently available
CXCR4 antibodies. Adjacent sections of a variety of human
tumors were dewaxed, microwaved in citric acid and incubated
with anti-CXCR4 {UMB-2} at a dilution of 1:10, 10 mg/ml anti-
CXCR4 {6190}, 15 mg/ml anti-CXCR4 {44716} or 25 mg/ml
anti-CXCR4 {12G5} antibodies. Sections were sequentially
treated with biotinylated secondary antibodies AB solution.
Sections were then developed in diaminobenzidine and lightly
counterstained with hematoxylin. Note that UMB-2 immunohis-
tochemistry allowed a clear distinction between CXCR4 positive
and CXCR4 negative tumors. Whereas anti-CXCR4 {44716}
and anti-CXCR4 {12G5} produced a predominant nuclear
staining, anti-CXCR4 {6190} produced no staining under
otherwise identical conditions. Scale bar 50 mm.
Found at: doi:10.1371/journal.pone.0004069.s002 (7.57 MB TIF)
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